• 1
    Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 2
    Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.
  • 3
    Baraclude (entecavir). US Prescribing Information. Wallingford, CT: Bristol-Myers Squibb Company, 2010.
  • 4
    Brown RSJ, Lok AS, Gish RG et al. Entecavir demonstrates consistent responses among baseline subgroups in the treatment of nucleoside-naive, HBeAg(+) and HBeAg(−) patients with chronic hepatitis B. Digestive Disease Week, Chicago, May 14–19, 2005 poster M913.
  • 5
    Yao G, Chen C, Lu W et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007; 1: 365372.
  • 6
    Gish RG, Tsai N, Pan C et al. Efficacy and safety of entecavir in nucleos(t)ide naïve asians with HBeAg-positive and -negative chronic hepatitis B: results from studies ETV-022/027. Hepatology 2010; 52: 561A.
  • 7
    Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26(Suppl. 1): 123130.